local_hospital

Bellvitge University Hospital

Address
lock Available on a paid plan

Cardiovascular and Metabolic Research

At Bellvitge University Hospital, clinical trials in cardiovascular diseases and metabolic disorders focus on conditions such as heart failure, atrial fibrillation, acute myocardial infarction, atherosclerotic cardiovascular disease, hypertension, and severe hypertriglyceridemia. These studies are designed to test new treatments, reduce major cardiovascular events, and improve long-term heart and vascular health.

  • Heart failure, including preserved and reduced ejection fraction, with a focus on improving cardiac function and outcomes
  • Atrial fibrillation and stroke prevention, especially in patients who need safer ways to lower clot-related risk
  • Acute coronary syndromes and myocardial infarction, with trials aimed at reducing inflammation and future cardiovascular events
  • Metabolic conditions such as hypertriglyceridemia and familial hypercholesterolemia, evaluating therapies that improve lipid control

This research reflects a strong interest in preventing complications and finding better ways to treat cardiovascular disease across both acute and chronic settings.

Kidney, Transplantation, and Renal Immunology

The site conducts extensive research in nephrology and transplant medicine, studying chronic kidney disease, IgA nephropathy, lupus nephritis, kidney transplant rejection, and end-stage renal disease. These trials aim to preserve kidney function, improve transplant outcomes, and evaluate new approaches for immune-related kidney injury.

  • Chronic and progressive kidney disease, including proteinuria and hypertension-related kidney damage
  • Kidney transplant complications such as antibody-mediated rejection, graft pyelonephritis, and delayed graft function
  • Immune-mediated renal diseases like IgA nephropathy and lupus nephritis, with trials testing targeted therapies
  • Renal replacement and dialysis-related studies, including treatments for inflammation and long-term kidney protection

This is one of the most active areas at Bellvitge University Hospital, with a clear emphasis on improving kidney survival and transplant care.

Respiratory and Infectious Disease Studies

Clinical research in respiratory diseases and infectious diseases includes COPD, asthma, idiopathic pulmonary fibrosis, bronchiectasis, pneumonia, respiratory syncytial virus infection, and serious bacterial infections. The purpose of these trials is to improve symptom control, reduce infections, and evaluate therapies for severe or progressive lung disease.

  • Chronic lung diseases such as COPD, asthma, bronchiectasis, and pulmonary fibrosis
  • Severe respiratory infections, including pneumonia, RSV, and bacterial bloodstream infections
  • Inflammatory and immune-related lung conditions, with studies seeking better disease control
  • Antimicrobial research aimed at improving treatment effectiveness and limiting complications

These trials support better management of both long-term breathing disorders and acute infections across the hospital’s respiratory research portfolio.

Neurology, Neuroimmunology, and Mental Health

The hospital is active in neurology, neuroimmunology, and psychiatry, with trials in multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, myasthenia gravis, Alzheimer’s disease, obsessive compulsive disorder, and major depressive disorder. Research here is focused on testing new therapies, slowing disease progression, and improving daily function and quality of life.

  • Multiple sclerosis and related progressive forms, including studies of long-term disease control
  • Neuromuscular disorders such as ALS, Becker muscular dystrophy, and myasthenia gravis
  • Seizure disorders and epilepsy, with trials exploring better symptom prevention and control
  • Mental health conditions, including depression and obsessive compulsive disorder, to evaluate ongoing treatment benefit

This broad program shows a strong commitment to both chronic neurological disease and brain health research at Bellvitge University Hospital.

Gastroenterology, Hepatology, and Immune-Mediated Disease

Research in digestive system diseases and immune system diseases includes Crohn’s disease, ulcerative colitis, advanced chronic liver disease, pancreatitis, and perianal fistulising disease. These trials are designed to improve disease control, reduce inflammation, and assess longer-term safety of new treatment options.

  • Inflammatory bowel disease, especially Crohn’s disease and ulcerative colitis
  • Chronic liver disease and liver-related complications, including prognosis-focused studies
  • Pancreatic and post-surgical digestive conditions, where better recovery and symptom control are key goals
  • Immune-mediated digestive disorders, evaluating therapies that target inflammation and tissue damage

The research portfolio combines symptom relief, disease modification, and long-term safety assessment in complex gastrointestinal conditions.

Ophthalmology and Vision Research

Trials in eye diseases address diabetic retinopathy, age-related macular degeneration, uveitis, thyroid eye disease, and pathologic myopia. The main aim is to preserve vision, slow disease progression, and evaluate therapies that may improve retinal and optic outcomes.

  • Diabetic eye disease, including retinopathy and its early progression
  • Macular degeneration and geographic atrophy, with studies focused on maintaining visual function
  • Inflammatory eye conditions such as uveitis and thyroid eye disease
  • Retinal vascular and choroidal disorders, where new treatments are being assessed for effectiveness

This area highlights ongoing efforts to protect eyesight through earlier intervention and improved treatment options.

Oncology and Hematology

The site also supports research in neoplasms and blood disorders, including bladder cancer, prostate cancer, lung cancer, uveal melanoma, gastrointestinal stromal tumor, and lymphoma. These studies are intended to evaluate new cancer therapies, improve disease control, and extend survival.

  • Urologic cancers such as high-risk and non-muscle invasive bladder cancer
  • Prostate cancer, including oligometastatic and metastatic disease
  • Solid tumors such as lung cancer and uveal melanoma
  • Hematologic malignancies, including B-cell lymphomas and related blood cancers

The oncology program reflects a wide-ranging effort to improve treatment options for both common and rare cancers.

Allergy, Dermatology, and Autoimmune Research

Clinical trials in allergy, skin disease, and autoimmune disorders include atopic dermatitis, psoriasis, chronic urticaria, allergic rhinitis, systemic lupus erythematosus, and systemic sclerosis. The goal is to test targeted therapies, reduce inflammatory symptoms, and improve everyday comfort and disease control.

  • Allergic conditions affecting the nose, eyes, and skin, with studies aimed at better symptom relief
  • Inflammatory skin diseases such as atopic dermatitis, psoriasis, hidradenitis suppurativa, and vitiligo
  • Systemic autoimmune diseases, including lupus and scleroderma, where immune control is central
  • Chronic urticaria and hereditary angioedema, focusing on reducing recurrent flare-ups and attacks

This research area combines common allergic disorders with complex immune-mediated diseases, broadening the hospital’s clinical trial reach.

Musculoskeletal, Rare Disease, and Endocrine Studies

Additional trials cover musculoskeletal diseases, rare genetic disorders, and endocrine conditions such as low back pain, Fabry disease, Niemann-Pick disease type C, thyroid disease, and type 1 diabetes. These studies are aimed at improving pain control, supporting long-term disease management, and evaluating treatments for uncommon conditions.

  • Chronic pain and inflammatory muscle disorders, including low back pain and idiopathic inflammatory myopathies
  • Rare inherited diseases such as Fabry disease and Niemann-Pick disease type C
  • Endocrine and metabolic conditions, including type 1 diabetes and thyroid-related disease
  • Selected genetic and connective tissue disorders, where new therapies are being explored

Together, these studies show the site’s interest in both everyday symptom management and specialized rare disease research.

Site Overview

assignment
364
connected trials
corporate_fare
181
sponsors
science
538
IMPs

Activity Indicator

Last 6 months

38
Trials started
-7% vs previous period.
41
Trials started 6–12 months ago
364
Total trials linked
Highly Active
trending_downDeclining-7%
12
5
5
6
7
3
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 33 therapeutic areas and 15 of 538 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 498 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
166
Sponsors (total)
181
Active sponsors
109

Sponsor Network

Top 109 by active trials.

lock +108 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +60 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
364
Outperforms 96% of sites
public
Therapeutic diversity
34areas
Outperforms 98% of sites
groups
Sponsor diversity
181sponsors
Outperforms 96% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Bellvitge University Hospital

lock Showing 1 of 364 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.Celltrion Inc.Phase IIINot RecruitingJan 2024

IMP list

lock Showing 1 of 538 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Emtricitabine11Unknown2016-12-132026-03-16

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.